Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant
Purpose: To observe the clinical effects of sirolimus (SRL) immunosuppressive therapy in patients with progressively increasing levels of serum creatinine (Scr) after renal transplant. Methods: In total, 180 patients whose Scr levels had been rising after renal transplant were given an oral calcineu...
Gespeichert in:
| Veröffentlicht in: | Tropical journal of pharmaceutical research 2016-05, Vol.15 (5), p.1077 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1077 |
| container_title | Tropical journal of pharmaceutical research |
| container_volume | 15 |
| creator | Pan, Zhen-Hong Zhang, Yan-Xuan Fang, Jun Qu, Qing-Shan Jiang, Xin Li, Ming |
| description | Purpose: To observe the clinical effects of sirolimus (SRL)
immunosuppressive therapy in patients with progressively increasing
levels of serum creatinine (Scr) after renal transplant. Methods: In
total, 180 patients whose Scr levels had been rising after renal
transplant were given an oral calcineurin inhibitor (CNI): either
cyclosporine A (CsA) or tacrolimus (FK506). All patients were treated
at People's Hospital of Zhengzhou, China, between January 2011
and December 2013, and were given SRL-based conversion treatment. Scr
level and glomerular filtration rate (GFR) were observed before and 1,
3, and 6 months after treatment initiation. In addition, liver
function, blood glucose, blood lipid levels, rejection reaction
incidence, and mortality were recorded to evaluate the effects of SRL.
Results: Scr levels were 116.60 ± 30.60 μmol/L and 119.00
± 24.60 μmol/L, and GFR was 70.00 ± 19.70 mL/min and
75.90 ± 15.60 mL/min, at 3 and 6 months after treatment,
respectively. The 3- and 6- month Scr and GFR values were statistically
different (p < 0.05) compared to pre-treatment levels (Scr: 144.10
± 61.70 μmol/L vs and GFR: 59.10 ± 16.20 mL/min. Acute
rejection (AR) occurred in 20 patients (13.30 %) within 6 months of
treatment initiation, but rejection was reversed with conventional
methylprednisolone therapy. Twenty-one patients (11.70 %) developed
lung infections, but all were cured. There were no significant
differences in liver function before and after treatment. Conclusion:
SRL-based immunosuppressive therapy is effective in treating patients
with increased Scr levels after renal transplant. |
| doi_str_mv | 10.4314/tjpr.v15i5.25 |
| format | Article |
| fullrecord | <record><control><sourceid>bioline_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4314_tjpr_v15i5_25</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>cria_bioline_pr_pr16144</sourcerecordid><originalsourceid>FETCH-LOGICAL-b315t-ade35188d87f7e408fd4626167182f2be558caed79d13d8780fc71816c74dc323</originalsourceid><addsrcrecordid>eNpFUE1LAzEUDKJgrR695w_suskm2exRil9Q8KLnJZu8YEo2XZO04r83tUXhwZs3Mwy8QeiWNDVrCbvLmznWe8Idryk_QwvCe1H1knbnJ8z7Xlyiq5Q2TcNF35MF-lx5F5xWHoO1oHPCW4uTi1vvpl3COYLKE4SMXcCzyq7AhL9c_iiELmICgxPE3YQPVy5ZAbCHPfiElc0QcYRQ0nNUIc1ehXyNLqzyCW5Oe4neHx_eVs_V-vXpZXW_rsaW8FwpAy0nUhrZ2Q5YI61hggoiOiKppSNwLrUC0_WGtMUkG6uLRITumNEtbZeoOubquE0pgh3m6CYVvwfSDIe-hkNfw29fA-XFXx_9oyvPB_iz6-jU8E-WIYIw1v4AvJlz3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant</title><source>DOAJ Directory of Open Access Journals</source><source>African Journals Online (Open Access)</source><source>Bioline International</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Pan, Zhen-Hong ; Zhang, Yan-Xuan ; Fang, Jun ; Qu, Qing-Shan ; Jiang, Xin ; Li, Ming</creator><creatorcontrib>Pan, Zhen-Hong ; Zhang, Yan-Xuan ; Fang, Jun ; Qu, Qing-Shan ; Jiang, Xin ; Li, Ming</creatorcontrib><description>Purpose: To observe the clinical effects of sirolimus (SRL)
immunosuppressive therapy in patients with progressively increasing
levels of serum creatinine (Scr) after renal transplant. Methods: In
total, 180 patients whose Scr levels had been rising after renal
transplant were given an oral calcineurin inhibitor (CNI): either
cyclosporine A (CsA) or tacrolimus (FK506). All patients were treated
at People's Hospital of Zhengzhou, China, between January 2011
and December 2013, and were given SRL-based conversion treatment. Scr
level and glomerular filtration rate (GFR) were observed before and 1,
3, and 6 months after treatment initiation. In addition, liver
function, blood glucose, blood lipid levels, rejection reaction
incidence, and mortality were recorded to evaluate the effects of SRL.
Results: Scr levels were 116.60 ± 30.60 μmol/L and 119.00
± 24.60 μmol/L, and GFR was 70.00 ± 19.70 mL/min and
75.90 ± 15.60 mL/min, at 3 and 6 months after treatment,
respectively. The 3- and 6- month Scr and GFR values were statistically
different (p < 0.05) compared to pre-treatment levels (Scr: 144.10
± 61.70 μmol/L vs and GFR: 59.10 ± 16.20 mL/min. Acute
rejection (AR) occurred in 20 patients (13.30 %) within 6 months of
treatment initiation, but rejection was reversed with conventional
methylprednisolone therapy. Twenty-one patients (11.70 %) developed
lung infections, but all were cured. There were no significant
differences in liver function before and after treatment. Conclusion:
SRL-based immunosuppressive therapy is effective in treating patients
with increased Scr levels after renal transplant.</description><identifier>ISSN: 1596-5996</identifier><identifier>EISSN: 1596-9827</identifier><identifier>DOI: 10.4314/tjpr.v15i5.25</identifier><language>eng</language><publisher>Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria</publisher><subject>Acute rejection ; Calcineurin inhibitors ; Glomerular filtration rate ; Renal transplant ; Serum creatinine ; Sirolimus</subject><ispartof>Tropical journal of pharmaceutical research, 2016-05, Vol.15 (5), p.1077</ispartof><rights>Copyright 2016 - Tropical Journal of Pharmaceutical Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b315t-ade35188d87f7e408fd4626167182f2be558caed79d13d8780fc71816c74dc323</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924,79297</link.rule.ids></links><search><creatorcontrib>Pan, Zhen-Hong</creatorcontrib><creatorcontrib>Zhang, Yan-Xuan</creatorcontrib><creatorcontrib>Fang, Jun</creatorcontrib><creatorcontrib>Qu, Qing-Shan</creatorcontrib><creatorcontrib>Jiang, Xin</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><title>Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant</title><title>Tropical journal of pharmaceutical research</title><description>Purpose: To observe the clinical effects of sirolimus (SRL)
immunosuppressive therapy in patients with progressively increasing
levels of serum creatinine (Scr) after renal transplant. Methods: In
total, 180 patients whose Scr levels had been rising after renal
transplant were given an oral calcineurin inhibitor (CNI): either
cyclosporine A (CsA) or tacrolimus (FK506). All patients were treated
at People's Hospital of Zhengzhou, China, between January 2011
and December 2013, and were given SRL-based conversion treatment. Scr
level and glomerular filtration rate (GFR) were observed before and 1,
3, and 6 months after treatment initiation. In addition, liver
function, blood glucose, blood lipid levels, rejection reaction
incidence, and mortality were recorded to evaluate the effects of SRL.
Results: Scr levels were 116.60 ± 30.60 μmol/L and 119.00
± 24.60 μmol/L, and GFR was 70.00 ± 19.70 mL/min and
75.90 ± 15.60 mL/min, at 3 and 6 months after treatment,
respectively. The 3- and 6- month Scr and GFR values were statistically
different (p < 0.05) compared to pre-treatment levels (Scr: 144.10
± 61.70 μmol/L vs and GFR: 59.10 ± 16.20 mL/min. Acute
rejection (AR) occurred in 20 patients (13.30 %) within 6 months of
treatment initiation, but rejection was reversed with conventional
methylprednisolone therapy. Twenty-one patients (11.70 %) developed
lung infections, but all were cured. There were no significant
differences in liver function before and after treatment. Conclusion:
SRL-based immunosuppressive therapy is effective in treating patients
with increased Scr levels after renal transplant.</description><subject>Acute rejection</subject><subject>Calcineurin inhibitors</subject><subject>Glomerular filtration rate</subject><subject>Renal transplant</subject><subject>Serum creatinine</subject><subject>Sirolimus</subject><issn>1596-5996</issn><issn>1596-9827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>RBI</sourceid><recordid>eNpFUE1LAzEUDKJgrR695w_suskm2exRil9Q8KLnJZu8YEo2XZO04r83tUXhwZs3Mwy8QeiWNDVrCbvLmznWe8Idryk_QwvCe1H1knbnJ8z7Xlyiq5Q2TcNF35MF-lx5F5xWHoO1oHPCW4uTi1vvpl3COYLKE4SMXcCzyq7AhL9c_iiELmICgxPE3YQPVy5ZAbCHPfiElc0QcYRQ0nNUIc1ehXyNLqzyCW5Oe4neHx_eVs_V-vXpZXW_rsaW8FwpAy0nUhrZ2Q5YI61hggoiOiKppSNwLrUC0_WGtMUkG6uLRITumNEtbZeoOubquE0pgh3m6CYVvwfSDIe-hkNfw29fA-XFXx_9oyvPB_iz6-jU8E-WIYIw1v4AvJlz3w</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Pan, Zhen-Hong</creator><creator>Zhang, Yan-Xuan</creator><creator>Fang, Jun</creator><creator>Qu, Qing-Shan</creator><creator>Jiang, Xin</creator><creator>Li, Ming</creator><general>Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria</general><scope>RBI</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20160501</creationdate><title>Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant</title><author>Pan, Zhen-Hong ; Zhang, Yan-Xuan ; Fang, Jun ; Qu, Qing-Shan ; Jiang, Xin ; Li, Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b315t-ade35188d87f7e408fd4626167182f2be558caed79d13d8780fc71816c74dc323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acute rejection</topic><topic>Calcineurin inhibitors</topic><topic>Glomerular filtration rate</topic><topic>Renal transplant</topic><topic>Serum creatinine</topic><topic>Sirolimus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Zhen-Hong</creatorcontrib><creatorcontrib>Zhang, Yan-Xuan</creatorcontrib><creatorcontrib>Fang, Jun</creatorcontrib><creatorcontrib>Qu, Qing-Shan</creatorcontrib><creatorcontrib>Jiang, Xin</creatorcontrib><creatorcontrib>Li, Ming</creatorcontrib><collection>Bioline International</collection><collection>CrossRef</collection><jtitle>Tropical journal of pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Zhen-Hong</au><au>Zhang, Yan-Xuan</au><au>Fang, Jun</au><au>Qu, Qing-Shan</au><au>Jiang, Xin</au><au>Li, Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant</atitle><jtitle>Tropical journal of pharmaceutical research</jtitle><date>2016-05-01</date><risdate>2016</risdate><volume>15</volume><issue>5</issue><spage>1077</spage><pages>1077-</pages><issn>1596-5996</issn><eissn>1596-9827</eissn><abstract>Purpose: To observe the clinical effects of sirolimus (SRL)
immunosuppressive therapy in patients with progressively increasing
levels of serum creatinine (Scr) after renal transplant. Methods: In
total, 180 patients whose Scr levels had been rising after renal
transplant were given an oral calcineurin inhibitor (CNI): either
cyclosporine A (CsA) or tacrolimus (FK506). All patients were treated
at People's Hospital of Zhengzhou, China, between January 2011
and December 2013, and were given SRL-based conversion treatment. Scr
level and glomerular filtration rate (GFR) were observed before and 1,
3, and 6 months after treatment initiation. In addition, liver
function, blood glucose, blood lipid levels, rejection reaction
incidence, and mortality were recorded to evaluate the effects of SRL.
Results: Scr levels were 116.60 ± 30.60 μmol/L and 119.00
± 24.60 μmol/L, and GFR was 70.00 ± 19.70 mL/min and
75.90 ± 15.60 mL/min, at 3 and 6 months after treatment,
respectively. The 3- and 6- month Scr and GFR values were statistically
different (p < 0.05) compared to pre-treatment levels (Scr: 144.10
± 61.70 μmol/L vs and GFR: 59.10 ± 16.20 mL/min. Acute
rejection (AR) occurred in 20 patients (13.30 %) within 6 months of
treatment initiation, but rejection was reversed with conventional
methylprednisolone therapy. Twenty-one patients (11.70 %) developed
lung infections, but all were cured. There were no significant
differences in liver function before and after treatment. Conclusion:
SRL-based immunosuppressive therapy is effective in treating patients
with increased Scr levels after renal transplant.</abstract><pub>Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria</pub><doi>10.4314/tjpr.v15i5.25</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1596-5996 |
| ispartof | Tropical journal of pharmaceutical research, 2016-05, Vol.15 (5), p.1077 |
| issn | 1596-5996 1596-9827 |
| language | eng |
| recordid | cdi_crossref_primary_10_4314_tjpr_v15i5_25 |
| source | DOAJ Directory of Open Access Journals; African Journals Online (Open Access); Bioline International; EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Acute rejection Calcineurin inhibitors Glomerular filtration rate Renal transplant Serum creatinine Sirolimus |
| title | Clinical effects of sirolimus treatment in patients with increased serum creatinine levels after renal transplant |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A32%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-bioline_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20effects%20of%20sirolimus%20treatment%20in%20patients%20with%20increased%20serum%20creatinine%20levels%20after%20renal%20transplant&rft.jtitle=Tropical%20journal%20of%20pharmaceutical%20research&rft.au=Pan,%20Zhen-Hong&rft.date=2016-05-01&rft.volume=15&rft.issue=5&rft.spage=1077&rft.pages=1077-&rft.issn=1596-5996&rft.eissn=1596-9827&rft_id=info:doi/10.4314/tjpr.v15i5.25&rft_dat=%3Cbioline_cross%3Ecria_bioline_pr_pr16144%3C/bioline_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |